DBH
Dopamine beta-hydroxylase
As of the edition of 20 October 2026, DBH (dopamine beta-hydroxylase, UniProt P09172) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09172
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Lungs and airways; Heart and blood vessels; Mental health; Chemically induced; Digestive system
- Registered trials of its drugs
- 16
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Zamicastat | Active | Phase 2 | none listed |
| Nepicastat | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Bial | Route A |
The other 2 companies at DBH
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at DBH, ranked, with the facts behind eachRequest access. Nothing is shown until you do.